J 2019

The value of anti-JCV antibody index assessment in multiple sclerosis patients treated with natalizumab with respect to demographic, clinical and radiological findings

KOLČAVA, Jan, Monika HULOVÁ, Yvonne BENEŠOVÁ, Josef BEDNAŘÍK, Pavel ŠTOURAČ et. al.

Basic information

Original name

The value of anti-JCV antibody index assessment in multiple sclerosis patients treated with natalizumab with respect to demographic, clinical and radiological findings

Authors

KOLČAVA, Jan (203 Czech Republic, belonging to the institution), Monika HULOVÁ (203 Czech Republic, belonging to the institution), Yvonne BENEŠOVÁ (203 Czech Republic, belonging to the institution), Josef BEDNAŘÍK (203 Czech Republic, belonging to the institution) and Pavel ŠTOURAČ (203 Czech Republic, guarantor, belonging to the institution)

Edition

MULTIPLE SCLEROSIS AND RELATED DISORDERS, OXFORD, ELSEVIER SCI LTD, 2019, 2211-0348

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30210 Clinical neurology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 2.889

RIV identification code

RIV/00216224:14110/19:00110102

Organization unit

Faculty of Medicine

DOI

UT WoS

000464532100033

Keywords in English

Multiple sclerosis; Progressive multifocal leukoencephalopathy; Natalizumab; JC virus; Magnetic resonance imaging

Tags

Tags

International impact, Reviewed
Změněno: 8/7/2019 09:20, Soňa Böhmová

Abstract

V originále

Background: Natalizumab-related progressive multifocal leukoencephalopathy (PML) is associated with the presence of anti-John Cunningham virus (JCV) antibodies. The aim of this investigation was to evaluate the long-term stability of anti-JCV antibody serum levels and their relation to various demographic, clinical and radiological characteristics in patients suffering from multiple sclerosis (MS). Methods: Seventy-eight relapsing-remitting MS patients treated with natalizumab and evaluated for the presence of serum anti-JCV antibodies over a time period of 1-6 years (3-11 samples) were included in the study. Anti-JCV antibody levels and their changes were correlated with various demographic, clinical and radiological findings. Results: Median follow-up time was 43.5 months, with a median of 5.3 samples available per patient. At baseline, 46 (59%) of the patients were seropositive. During follow-up, anti-JCV antibody status changed from negative to positive or vice versa in 23% of patients. Baseline anti-JCV antibody index correlated positively with age (p = 0.03). Patients: with stable positive anti-JCV antibody index had more T2 hyperintensities (20.2 vs. 13.1; p < 0.007) on cerebral magnetic resonance imaging (MRI) and were also older than the stable negative anti-JCV antibody index group of patients (45.2.vs. 40.3 years; p < 0.01). No significant increase in T2 hyperintensities after seroconversion was revealed. Average duration from beginning of natalizumab therapy to seroconversion fit = 13) was 33 months. Annual seroconversion rate of anti-JCV antibody status was 6.5%. A baseline anti-JCV antibody index of > 0.90 (tt = 33) predicted stable seropositivity (100%), while baseline anti-JCV antibody index <0.20 did not predicted stable seronegativity (59%). PML was not diagnosed in any of the patients studied during the follow-up. Conclusions: A positive baseline anti-JCV antibody index of > 0.90 predicts stable positive JCV serostatus, in contrast with a baseline anti-JCV antibody index of <0.20, which remained negative in 59% of cases. Stable positive anti-JCV index patients have more MRI T2 hyperintensities and are older compared with stable negative anti-JCV index patients.